Skip to content

Net Income at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$5.24B-52.4%
Amgen logo
AmgenAMGN
$1.82B+5.1%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$1.03B+59.6%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
-$40.83M-38.4%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-$49.66M-2.4%
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
-$17.64M+0.4%

Other financials

Income statement

See full
Operating income-$35.2M-5.6%
Net income-$219.6M-576%
EPS (diluted)-$5.11+1.9%

Balance sheet

See full
Cash & equivalents$169.9M+239%
Total debt$2.9M-90.5%
Total equity-$150.4M-328%
Total assets$506.7M+364%

Cash flow

See full
Operating cash flow-$38.2M-23.1%
CapEx$48.0K-79.2%
Free cash flow-$38.3M-22.4%

Valuation

See full
Market cap$784.61M+2,513%
Enterprise value$617.68M+5,639%

Returns & leverage

See full
Return on equity-125.4%+671pp
Debt / equity0.5×+0.2×
Current ratio31.1×+27.3×

Where this comes from

Reported directly by Vor Biopharma in its filing.

Tagged under the XBRL concept us-gaap:ProfitLoss.

The official record: Vor Biopharma’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vor Biopharma's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vor Biopharma's net income?
Vor Biopharma (VOR) reported net income of -$219.59M in Q1 2026.
How has Vor Biopharma's net income changed year-over-year?
Vor Biopharma's net income decreased by 575.9% year-over-year, from -$32.49M to -$219.59M.
What is the long-term trend for Vor Biopharma's net income?
Over 3 years (2021 to 2024), Vor Biopharma's net income has grown at a 19.3% compound annual growth rate (CAGR), from -$68.9M to -$116.91M.
What does net income mean?
Net income as the starting point for the indirect method operating cash flow reconciliation.